Jitesh P. Jani

Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271

W. Gregory Roberts, Ethan Ung, Pamela Whalen et al. · Cancer Research · 2008 · 379 citations · Full text

Antitumor Activity, Cell Adhesion, Focal Adhesion Plaques +18

Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design

Ping Wei, Marlena Walls, Ming Qiu et al. · Molecular Cancer Therapeutics · 2010 · 194 citations · Full text

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Jean S. Beebe, Jitesh P. Jani, Elisabeth Knauth et al. · PubMed · 2003 · 128 citations

Cancer Therapy, Pharmacological Characterization, Tumor Biology +21

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).

Craig A. Dionne, Anna Marie Camoratto, Jitesh P. Jani et al. · PubMed · 1998 · 113 citations

Pathology, Cell Death, Prostate Adenocarcinoma +19

Bleomycin hydrolase: molecular cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase family

John E. Mignano, Jitesh P. Jani, S. Srimatkandada et al. · Biochemistry · 1989 · 104 citations